Key Highlights
- Second-quarter revenue was $678.2 million versus a $647.6 million consensus.
- Adjusted EPS was $0.23 versus $0.18 expected.
- Fortrea agreed to buy Early Phase Services from Worldwide Clinical Trials for $45 million.
- Barclays upgraded to Overweight while BofA rates the shares Underperform.
Fortrea Holdings Inc. (NASDAQ:FTRE), a contract research organisation serving drug developers, is attracting differing analyst opinions as it heads toward third-quarter results. It has a market capitalisation near $1.96 billion. Recent rating changes, from a Barclays upgrade to Overweight to a BofA Underperform, suggest investors hold varied views about the recovery.
Latest Company Context
Fortrea reported second-quarter 2026 results on July 29, 2026, with revenue of $678.2 million versus a $647.6 million consensus and adjusted EPS of $0.23 versus $0.18. The company raised full-year guidance. Trailing-twelve-month revenue is $2.68 billion, with a net loss of $85.2 million. In September, Fortrea agreed to acquire the Early Phase Services division of Worldwide Clinical Trials for $45 million.
Key Business Drivers
CRO results hinge on bookings, backlog conversion and biotech funding conditions, which influence demand for clinical trial services. A beat on revenue and earnings followed by a guidance raise may indicate improving execution, but trailing losses show profitability remains a work in progress. The early-phase acquisition could broaden services, subject to integration. Analyst moves illustrate the range: Barclays upgraded to Overweight with a $23 target, UBS initiated at Neutral with $22, and BofA raised its target to $15.50 from $13 while keeping Underperform. Such dispersion implies uncertainty about the pace of improvement.
What Investors Should Watch
Investors may watch the third-quarter results for book-to-bill, backlog, adjusted EBITDA and any further change to full-year guidance. Biotech funding conditions, cancellation trends, debt reduction progress and completion of the Worldwide Clinical Trials division purchase could be additional catalysts. Further analyst changes around the report may influence sentiment.
A Revenue Beat and Split Ratings Frame the Recovery Story
Fortrea heads into its third-quarter report with a revenue beat, raised guidance and sharply split analyst ratings. The $45 million Early Phase Services acquisition adds a new piece to the recovery story.






Please wait processing your request...